← All trials
NCT03171389
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2017
- Primary completion
- Sep 22, 2018
- Completion date
- Sep 22, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 81
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universität Duisburg-EssenLead sponsor
- WiSP GmbHCollaborator
- RWTH Aachen UniversityCollaborator
- University of TuebingenCollaborator
- University of MannheimCollaborator
- University of Duisburg-EssenOverall official - principal investigator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- University of Duisburg-EssenSponsor investigator
- University of Witten/HerdeckeCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.